Smart Hydrogel Combining CBD and FGF21 Accelerates Spinal Cord Injury Recovery
An injectable hydrogel co-delivering cannabidiol and FGF21 reduces spinal cord inflammation and restores motor function in mice.
Summary
Researchers developed an injectable hydrogel called C/F/Gel, loaded with fibroblast growth factor 21 (FGF21) and cannabidiol micelles (CBDm), to treat spinal cord injury (SCI). The hydrogel is composed of PF127 and alpha-cyclodextrin, enabling sustained, stable drug release at the injury site. By activating cannabinoid receptor 2 (CB2R), C/F/Gel shifts microglia—immune cells in the brain and spinal cord—toward an anti-inflammatory state (M2 phenotype), dampening the destructive inflammation typical of SCI. The hydrogel also helps restore the balance between excitatory and inhibitory neurons, a critical factor in functional recovery. In SCI mouse models, C/F/Gel outperformed single-agent treatments across behavioral, histological, and molecular measures, significantly improving motor function and highlighting the synergistic power of combining neuroprotective and anti-inflammatory agents in a smart delivery system.
Detailed Summary
Spinal cord injury (SCI) remains one of medicine's most challenging conditions, causing permanent motor and sensory deficits in millions worldwide. The injury cascade involves rapid inflammation, neuronal death, and disruption of neural circuits, making multi-target treatment strategies essential. Current therapies are largely inadequate, underscoring the urgent need for innovative approaches.
In this study, researchers from Wenzhou Medical University engineered an injectable hydrogel platform—C/F/Gel—co-loaded with fibroblast growth factor 21 (FGF21) and cannabidiol micelles (CBDm). The hydrogel matrix, built from poloxamer 407 (PF127) and alpha-cyclodextrin (α-CD), was designed to provide sustained, localized drug release while enhancing the stability of both agents at the injury site—a significant formulation challenge given CBD's poor water solubility.
The dual-agent system worked through complementary mechanisms. CBDm activated cannabinoid receptor 2 (CB2R) on microglia, driving polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, effectively calming the inflammatory microenvironment. Meanwhile, FGF21 contributed neuroprotective and neuroregenerative effects, and together the agents restored the balance between excitatory and inhibitory neurotransmission—a balance often catastrophically disrupted after SCI.
In SCI mouse models, C/F/Gel demonstrated significantly superior outcomes compared to either FGF21 or CBDm alone. Behavioral assessments showed improved motor function, while histological and molecular analyses confirmed reduced inflammation, preserved neural tissue, and enhanced circuit integrity.
These findings position C/F/Gel as a compelling biomaterial-based strategy for SCI, integrating inflammation control, neuroprotection, and functional restoration in a single injectable platform. However, results are currently limited to mouse models, and the translational path to human clinical application will require extensive safety, pharmacokinetic, and efficacy validation in larger animal models and eventually clinical trials.
Key Findings
- C/F/Gel hydrogel co-delivering FGF21 and CBD micelles outperformed single-agent treatments in SCI mouse models.
- CB2R activation by cannabidiol shifted microglia to anti-inflammatory M2 phenotype, reducing neuroinflammation.
- The PF127/α-cyclodextrin matrix enabled sustained local drug release and improved CBD stability at injury site.
- C/F/Gel restored excitatory/inhibitory neuron balance, a critical factor in motor and sensory circuit recovery.
- Behavioral, histological, and molecular outcomes all confirmed superior neuroprotection and functional recovery with combination therapy.
Methodology
Researchers used a mouse SCI model to test an injectable hydrogel (C/F/Gel) composed of PF127 and α-cyclodextrin co-loaded with FGF21 and cannabidiol micelles. Outcomes were evaluated via behavioral assessments, histological analysis, and molecular studies comparing C/F/Gel to single-agent controls. Mechanistic studies focused on CB2R-mediated microglial polarization and excitatory/inhibitory neuron balance.
Study Limitations
All experiments were conducted in mice, and translational relevance to human SCI—which involves more complex anatomy and injury heterogeneity—remains to be established. Long-term safety data, biodegradation profiles of the hydrogel, and pharmacokinetic behavior in larger animal models are not yet reported. The study is based solely on the abstract, so detailed methodological and statistical information could not be fully evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: